|
|
|
| Value of NSE, ProGRP, CYFRA21-1 and CEA for chemotherapy efficacy evaluation in patients with limited and extensive stage of small cell lung cancer |
| ZHOU Xusheng1,2 CUI Zhaolei1,2 LIN Yingying1,2 HU Minhua1,2 CHEN Yan1,2 |
1.Department of Clinical Laboratory, Fujian Cancer Hospital Fujian Medical University Cancer Hospital, Fujian Province, Fuzhou 350014, China;
2.Biochemistry and Molecular Biology Laboratory, Fujian Cancer Hospital Fujian Medical University Cancer Hospital, Fujian Province, Fuzhou 350014, China |
|
|
|
Abstract Objective To investigate the value of neuron specific enolase (NSE), pro-gastrin-releasing peptide (ProGRP), soluble fragment of cytokeratin 19 (CYFRA21-1) and carcinoembryonic antigen (CEA) for chemotherapy efficacy evaluation in patients in limited stage (LS) or extensive stage (ES) of small cell lung cancer (SCLC). Methods A total of 247 SCLC patients, first visit and after 2 cycles of chemotherapy, were selected from January 2014 to December 2016 in Fujian Cancer Hospital, and 86 patients in LS group (first visit 44 cases, after 2 cycles of chemotherapy 42 cases) and 161 in ES group (first visit 98 cases, after 2 cycles of chemotherapy 63 cases). Expression levels of serum NSE, ProGRP, CYFRA21-1 and CEA of patients were detected via electrochemiluminescence assay before and after treatment. Results Levels of serum NSE, ProGRP, CYFRA21-1 in the two groups were significantly lower after treatment than those before treatment (P ＜ 0.05). Spearman correlation analysis manifested that, in LS group NSE level was positively correlated to ProGRP and CYFRA21-1 levels, and the expression of CYFRA21-1 was positively correlated to ProGRP and CEA levels (P ＜ 0.05). In ES group either two indicators were positively correlated to the other (P ＜ 0.01). NSE had the highest value of areas under the ROC curve in both groups (LS group: 0.924, ES group: 0.920), with secondly ProGRP (LS group: 0.823, ES group: 0.820), that were both higher than CYFRA21-1 (LS group: 0.748, ES group: 0.806) and CEA (LS group: 0.589, ES group: 0.660). Moreover, the sensitivity of NSE in assessing treatment efficacy in LS group AND ES group was 86.4% and 95.9%, respectively, and the specificity was 92.9% and 79.4%, respectively. Conclusion NSE, ProGRP, CYFRA21-1 and CEA could be biomarkers in evaluation of chemotherapy efficacy in patients with SCLC, and NSE and ProGRP retain relatively higher sensitivity and specificity.
|
|
|
|
|
|
[1] Chen W，Zheng R，Baade PD，et al. Cancer statistics in China，2015 [J]. CA Cancer J Clin，2016，66（2）：115-132.
[2] Glatzer M，Schmid S，Radovic M，et al. The role of radiation therapy in the management of small cell lung cancer [J]. Breathe（Sheff），2017，13（4）：e87-e94.
[3] 支修益.小细胞肺癌生物标志物临床应用进展[J].中国医学前沿杂志：电子版，2017，9（3）：1-7.
[4] Neal JW，Gubens MA，Wakelee HA. Current management of small cell lung cancer [J]. Clin Chest Med，2011，32（4）：853-863.
[5] Lu H，Jiang Z. Advances in antibody therapeutics targeting small-cell lung cancer [J]. Adv Clin Exp Med，2018：doi：10.17219/acem/70159.
[6] Roca E，Gurizzan C，Amoroso V，et al. Outcome of patients with lung adenocarcinoma with transformation to small-cell lung cancer following tyrosine kinase inhibitors treatment：A systematic review and pooled analysis [J]. Cancer Treat Rev，2017，59：117-122.
[7] Li Q，Wu T，Jing L，et al. Angiogenesis inhibitors for the treatment of small cell lung cancer（SCLC）：A meta-analysis of 7 randomized controlled trials [J]. Medicine（Baltimore），2017，96（13）：e6412.
[8] Oronsky B，Reid TR，Oronsky A，et al. What′s New in SCLC? A Review [J]. Neoplasia，2017，19（10）：842-847.
[9] Liu L，Teng J，Zhang L，et al. The Combination of the Tumor Markers Suggests the Histological Diagnosis of Lung Cancer [J]. Biomed Res Int，2017：2013989.
[10] Molina R，Augé JM，Bosch X，et al. Usefulness of serum tumor markers，including progastrin-releasing peptide，in patients with lung cancer：correlation with histology [J]. Tumour Biol，2009，30（3）：121-129.
[11] Huang Z，Xu D，Zhang F，et al. Pro-gastrin-releasing peptide and neuron-specific enolase：useful predictors of response to chemotherapy and survival in patients with small cell lung cancer [J]. Clin Transl Oncol，2016，18（10）：1019-1025.
[12] Wojcik E，Kulpa JK. Pro-gastrin-releasing peptide（ProGRP）as a biomarker in small-cell lung cancer diagnosis， monitoring and evaluation of treatment response [J]. Lung Cancer（Auckl），2017，8：231-240.
[13] Jiang ZF，Wang M，Xu JL. Thymidine kinase 1 combined with CEA，CYFRA21-1 and NSE improved its diagnostic value for lung cancer [J]. Life Sci，2018，194：1-6.
[14] 沈隽霏，吴文浩，周佳烨，等.电化学发光法检测胃泌素释放肽前体的性能评价及临床应用评估[J].检验医学，2018，33（3）：222-227.
[15] 单新洁，祁晓婷，俞荣，等.4项血清肿瘤标志物联合检测在肺癌中的应用价值分析[J].河北医科大学学报，2018， 39（7）：833-837.
[16] 罗家友，周凌燕，张丽娟，等.呼出气冷凝液CEA、P53蛋白、miRNA21检测对孤立性肺结节早期肺癌的诊断价值及临床相关性研究[J].中国现代医生，2018，56（7）：5-8，169.
[17] Niho S，Nishiwaki Y，Goto K，et al. Significance of serum pro-gastrin-releasing peptide as a predictor of relapse of small cell lung cancer：comparative evaluation with neuron-specific enolase and carcinoembryonic antigen [J]. Lung Cancer，2000，27（3）：159-167.
[18] Wang L，Wang D，Zheng G，et al. Clinical evaluation and therapeutic monitoring value of serum tumor markers in lung cancer [J]. Int J Biol Markers，2016，31（1）：e80-e87.
[19] 李龙飞，渠敬明，王祥军，等.不同类型肺癌患者化疗前后血清CEA、NSE及CYFRA21-1的表达及意义[J].中国老年学杂志，2018，38（4）：821-823.
[20] 汤建华，张鹤鸣，庞茜茜，等.重组人血管内皮抑制素联合顺铂对Lewis肺癌小鼠肿瘤微环境的影响[J].临床和实验医学杂志，2018，17（1）：34-36.
[21] 刘颖，李华强，罗治海，等.CEA、NSE、CYFRA21-1联合检测对肺癌的早期诊断价值[J].医学综述，2016，22（9）：1774-1776.
[22] 常哲兴，高云东，张雪峰，等.肺癌患者化疗前后CEA、NSE、SCC-Ag和CYFRA21-1的表达及意义[J].中国实验诊断学，2014，18（11）：1813-1816.
[23] 江海涛，阮磊，杨建涛，等.小细胞肺癌的CT表现与肿瘤标志物NSE、CYF21-1、CEA的相关性研究[J].中国现代医生，2018，56（12）：16-19.
[24] 杜强强，韩波.CEA、CTC在非小细胞肺癌中的研究进展[J].癌症进展，2016，14（10）：958-961.
[25] 李德经，宁国兰，柳兆飞，等.ProGRP和NSE对小细胞肺癌的诊断及疗效评估的价值[J].实用医学杂志，2016， 32（5）：754-758.
[26] 赵云龙，丁程，姜博伦，等.胃泌素释放肽前体对小细胞肺癌诊治的临床意义[J].癌症进展，2016，14（2）：142-145. |
|
|
|
